Frequently Asked Questions
What is European Market Access consulting?
European Market Access consulting focuses on designing and coordinating reimbursement, pricing and HTA strategies across multiple European countries, ensuring consistency, risk control and sustainable access.
How is Euro Axxess Partners different from traditional consultancies?
Unlike traditional consultancies, Euro Axxess Partners operates through a network of senior national experts governed by a central European strategy, preventing fragmentation and pricing spill-over risks.
How do you manage pricing spill-over across Europe?
We define European pricing corridors, reference baskets and escalation rules upfront, ensuring that national price decisions do not undermine European value.
Do you support Joint Clinical Assessments (JCAs)?
Yes. We align European clinical narratives with national reimbursement logic, ensuring JCA outcomes strengthen – not fragment – national access strategies.
Which countries do you cover?
We work across all major European markets, coordinated under a single European governance model.
Key terms
1
European Market Access Strategy
A coordinated European approach to pricing, reimbursement and HTA that ensures national implementation aligns with overarching European objectives and value preservation.
2
Health Technology Assessment
HTA is a formal evaluation of a medicine’s clinical benefit, added value and, in some countries, cost-effectiveness, used by payers to inform reimbursement decisions.
3
European Reimbursement Pathways
The country-specific processes and decision routes through which medicines achieve reimbursement and market access across European healthcare systems.
4
International Reference Pricing
IRP is a pricing mechanism where countries reference prices from other markets to inform or constrain national pricing decisions, creating cross-country interdependencies
5
European Pricing Corridor
A defined European price range within which national prices can be negotiated, protecting pricing consistency and limiting spill-over risks across markets.
6
Joint Clinical Assessment
JCA is an European-level assessment of clinical evidence under the EU HTA framework, intended to support national reimbursement decisions while reducing duplication.